CoChat

Observational follow‐up of the PROactive study: a 6‐year update

Erdmann, E., Song, E., Spanheimer, R., van Troostenburg de Bruyn, A.‐R., Perez, A. · 2014 · Diabetes, Obesity and Metabolism
Cited by 65

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Aims: The PROactive study investigated pioglitazone for secondary prevention of macrovascular events in type 2 diabetes mellitus. Pioglitazone showed a 10% (non‐significant) relative risk (RR) reduction for the primary composite endpoint and a significant 16% reduction for the main secondary endpoint (death, myocardial infarction, stroke) after a mean 34.5 months. There was no difference in cumulative malignancy incidence, but an imbalance in bladder malignancies (pioglitazone 14, placebo 5). We present a pre‐specified 6‐year interim analysis of a 10‐year observational follow‐up. Methods: Any patient completing PROactive was eligible. No study treatments were provided. A Cox proportional hazard model compared non‐adjudicated macrovascular events (same endpoints as PROactive excluding acute coronary syndrome) based on original randomization. Malignancies were compared using conventional RR ratios. Results: Of 5238 randomized patients, 3599 (74%) entered the follow‐up. For the follow‐up (mean 5.8 years) or combined double‐blind and follow‐up periods (≤9.5 years, mean 8.7), there were no statistically significant differences in primary or main secondary endpoints. For the combined period, a similar percentage of patients had any diagnosed malignancy ( RR = 1.05, 95% CI [0.89, 1.24]) or bladder malignancy ( RR = 1.06, 95% CI [0.59, 1.89]) in the pioglitazone and placebo groups. There were fewer cases of bladder malignancy with pioglitazone (15 [0.6%] vs. 19 [0.7%] for placebo) for the combined period when events diagnosed in the first 365 days were excluded, and fewer cases for the follow‐up period alone (10 [0.5%] vs. 17 [1.0%] for placebo). Further analyses of pioglitazone use (including use during follow‐up) found no significant difference in bladder malignancies between any and no pioglitazone use for the combined period. Conclusions: These data suggest that improved macrovascular outcomes seen with pioglitazone subside without continued pioglitazone treatment. The double‐blind period bladder cancer imbalance did not persist in follow‐up.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12180

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 65

Metadata

Authors
Erdmann, E., Song, E., Spanheimer, R., van Troostenburg de Bruyn, A. ‐., & Perez, A.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2013-08-19
Volume
16
Issue
1
Pages
63-74
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2080070851
Cited by
65
References
8
FWCI
8.02
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Observational follow‐up of the PROactive study: a 6‐year update. https://app.cochat.ai/papers/10.1111/dom.12180
The paper
Erdmann, E., Song, E., Spanheimer, R., van Troostenburg de Bruyn, A. ‐., & Perez, A. (2014). Observational follow‐up of the PROactive study: a 6‐year update. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12180

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.